ProfileGDS5678 / 1417193_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 93% 94% 96% 95% 94% 94% 95% 95% 95% 92% 94% 93% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.8522593
GSM967853U87-EV human glioblastoma xenograft - Control 27.9525993
GSM967854U87-EV human glioblastoma xenograft - Control 38.0838494
GSM967855U87-EV human glioblastoma xenograft - Control 49.110396
GSM967856U87-EV human glioblastoma xenograft - Control 58.4018195
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.0453694
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.9463894
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.3499895
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.2646295
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.338195
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.6435792
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.0866594
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.8998293
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.8978793